Merck & Company, Inc. (NYSE:MRK)‘s stock had its “buy” rating restated by BMO Capital Markets in a research report issued on Friday. They presently have a $72.00 price target on the stock. BMO Capital Markets’ price target would indicate a potential upside of 11.94% from the stock’s previous close.

A number of other analysts have also recently weighed in on the stock. Jefferies Group LLC restated a “sell” rating and issued a $52.00 price target on shares of Merck & in a report on Sunday, August 20th. J P Morgan Chase & Co raised their price target on shares of Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Vetr upgraded shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price target on the stock in a report on Monday, May 15th. Finally, Credit Suisse Group lowered their price target on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating on the stock in a report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. Merck & presently has a consensus rating of “Hold” and a consensus target price of $69.68.

Shares of Merck & (NYSE MRK) traded down 0.241% on Friday, reaching $64.165. 2,867,994 shares of the company’s stock traded hands. The company has a market cap of $175.00 billion, a PE ratio of 34.740 and a beta of 0.81. Merck & has a 12-month low of $58.29 and a 12-month high of $66.80. The stock has a 50-day moving average price of $62.94 and a 200-day moving average price of $63.72.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same period last year, the business earned $0.93 EPS. The company’s revenue was up .9% compared to the same quarter last year. Equities research analysts anticipate that Merck & will post $3.88 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Merck & Company, Inc. (MRK) Earns “Buy” Rating from BMO Capital Markets” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/08/merck-company-inc-mrk-earns-buy-rating-from-bmo-capital-markets.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. Klingenstein Fields & Co. LLC raised its position in Merck & by 5.4% during the 1st quarter. Klingenstein Fields & Co. LLC now owns 446,450 shares of the company’s stock worth $28,368,000 after buying an additional 22,958 shares during the last quarter. First PREMIER Bank raised its position in Merck & by 2.7% during the 1st quarter. First PREMIER Bank now owns 21,475 shares of the company’s stock worth $1,364,000 after buying an additional 570 shares during the last quarter. Agran Libbie raised its position in Merck & by 83.0% during the 1st quarter. Agran Libbie now owns 11,918 shares of the company’s stock worth $757,000 after buying an additional 5,404 shares during the last quarter. Stevens Capital Management LP purchased a new position in Merck & during the 1st quarter worth approximately $15,126,000. Finally, Doyle Wealth Management purchased a new position in Merck & during the 1st quarter worth approximately $4,652,000. 73.02% of the stock is owned by institutional investors.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.